-
2008
12 February 2008: Press release no. 1, 2008: Phase III program for AVE0010/ZP10 licensed ...
-
Product Pipeline
Pipeline with 1 compound in phase III, 2 compounds in phase II, 3 compounds in phase I and ...
-
Available Positions
We have one vacant position: Scientist-Department of Molecular Pharmacology ...
About Us
Zealand Pharma is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative peptide-based products that target indications of significant unmet clinical need and commercial potential. Zealand Pharma’s specialized know-how in peptide chemistry enables the generation of novel peptide molecules with unique therapeutic qualities. The Company focuses on optimizing and developing well-understood peptides with known mechanisms.
Since 1999, Zealand’s scientists have built a pipeline that includes three compounds in clinical phase II development and two compounds in clinical phase I development. In addition, two compounds are in pre-clinical development.
As part of the Company’s operations, Zealand Pharma has formed clinical development partnerships with the leading pharmaceutical companies, Sanofi-Aventis and Wyeth.
Zealand Pharma’s proprietary SIPTM-technology aims to optimize the therapeutic profile of peptides by enhancing a compound’s distribution and persistence in the human body, thereby enhancing its efficacy. The SIPTM-technology has an additional advantage in that it can be applied to a broad range of active peptides.
Zealand Pharma is based in Copenhagen and has approximately 65 employees.
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.